NDAORAL-21TABLET
Approved
Mar 1964
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 12h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NORINYL 1+50 21-DAY is an oral contraceptive containing mestranol (estrogen) and norethindrone (progestin) in a 21-day tablet regimen. It prevents pregnancy through hormonal suppression of ovulation. This product represents a foundational oral contraceptive from the 1960s era.
LOE Approaching
Product is in late-stage decline with minimal commercial infrastructure; career opportunity is limited to legacy brand maintenance or transition roles.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Career opportunity on NORINYL 1+50 is minimal and declining; the product is approaching or in end-of-life stage with no linked job openings in the database. Assignment to this brand signals maintenance/legacy management rather than growth exposure, limiting career momentum.
Brand Manager (Legacy Products)Field Sales Representative (if retained)
Worked on NORINYL 1+50 21-DAY at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.